PhotonPharma's lead product, Innocell™, is an innovative therapy targeting advanced ovarian cancer and a range of solid organ tumors. The company focuses on personalized medicine that leverages the body’s immune system to fight disease. In February 2024 PhotonPharma received FDA clearance to initiate clinical development of Innocell™. The company plans to begin a Phase I trial, expected to enroll its first patient in Q4 2024. PhotonPharma raised $2.5M in Seed funding to support the Phase I clinical trial. The company is led by CEO Dr. Alan Rudolph and is based in Fort Collins, Colorado.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Aug 2024